Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ATNX Athenex (ATNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Athenex Stock (NASDAQ:ATNX) 30 days 90 days 365 days Advanced Chart Ad Insiders ExposedTop secret Trump trades?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Athenex alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.20▼$1.5252-Week Range N/AVolume1.88 million shsAverage Volume194,316 shsMarket Capitalization$1.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Read More… Top secret Trump trades? (Ad)As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Athenex Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks4th Percentile Overall ScoreATNX MarketRank™: Athenex scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Athenex. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Athenex is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athenex is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ATNX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAthenex does not currently pay a dividend.Dividend GrowthAthenex does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-1.97 Short InterestThere is no current short interest data available for ATNX. News and Social Media0.6 / 5News SentimentN/A Search Interest17 people have searched for ATNX on MarketBeat in the last 30 days. This is an increase of 143% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Athenex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Athenex is held by insiders.Percentage Held by InstitutionsOnly 30.48% of the stock of Athenex is held by institutions.Read more about Athenex's insider trading history. Receive ATNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNX Stock News HeadlinesBiopharmaceutical company expands in time to take on Athenex businessDecember 26, 2023 | bizjournals.comOnly 2 local CEOs score highly with both employees and investorsNovember 22, 2023 | bizjournals.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… November 24, 2024 | Crypto 101 Media (Ad)Athenex assets sold in bankruptcy auction; top executives dismissedJuly 31, 2023 | bizjournals.comAthenex (NASDAQ: ATNX)June 11, 2023 | fool.comBuffalo's drug development scene expected to continue in Athenex's wakeJune 1, 2023 | bizjournals.comAthenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-AugustMay 17, 2023 | bizjournals.comAthenex, Inc. (ATNX) stock price, news, quote & history – Yahoo FinanceMay 16, 2023 | uk.finance.yahoo.comSee More Headlines ATNX Stock Analysis - Frequently Asked Questions How were Athenex's earnings last quarter? Athenex, Inc. (NASDAQ:ATNX) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.08. The company earned $32.30 million during the quarter, compared to analysts' expectations of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%. When did Athenex IPO? Athenex (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager. What other stocks do shareholders of Athenex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athenex investors own include TherapeuticsMD (TXMD), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO), NVIDIA (NVDA), Tesla (TSLA) and Ford Motor (F). Company Calendar Last Earnings11/04/2021Today11/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATNX CUSIPN/A CIK1300699 Webwww.athenex.com Phone(716) 427-2950FaxN/AEmployees652Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($15.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-103,430,000.00 Net Margins-86.31% Pretax Margin-95.92% Return on Equity-727.79% Return on Assets-44.44% Debt Debt-to-Equity Ratio3.08 Current Ratio1.09 Quick Ratio0.72 Sales & Book Value Annual Sales$102.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($3.07) per share Price / BookN/AMiscellaneous Outstanding Shares8,660,000Free Float7,866,000Market Cap$1.76 million OptionableOptionable Beta1.36 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ATNX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredOne coin could soar when Trump’s elected …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athenex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.